首页> 美国卫生研究院文献>Journal of Clinical Biochemistry and Nutrition >Exendin-4 induces extracellular-superoxide dismutase through histone H3 acetylation in human retinal endothelial cells
【2h】

Exendin-4 induces extracellular-superoxide dismutase through histone H3 acetylation in human retinal endothelial cells

机译:Exendin-4通过人视网膜内皮细胞中的组蛋白H3乙酰化诱导细胞外超氧化物歧化酶

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Extracellular-superoxide dismutase (genetic name SOD3) is a secreted anti-oxidative enzyme, and its presence in vascular walls may play an important role in protecting the vascular system against oxidative stress. Oxidative stress has been implicated in the pathogenesis of diabetic retinopathy; therefore, increases in extracellular-superoxide dismutase have been suggested to inhibit the progression of diabetic retinopathy. Incretin-based drugs such as glucagon-like peptide-1 receptor agonists are used in the treatment of type 2 diabetes. Glucagon-like peptide-1 receptor agonists are expected to function as extrapancreatic agents because the glucagon-like peptide-1 receptor is expressed not only in pancreatic tissues, but also in many other tissue types. We herein demonstrated that exendin-4, a glucagon-like peptide-1 receptor agonist, induced the expression of extracellular-superoxide dismutase in human retinal microvascular endothelial cells through epigenetic regulation. The results of the present study demonstrated that exendin-4 induced the expression of extracellular-superoxide dismutase through histone H3 acetylation at the SOD3 proximal promoter region. Moreover, plasma extracellular-superoxide dismutase concentrations in diabetic patients were elevated by incretin-based therapies. Therefore, incretin-based therapies may exert direct extrapancreatic effects in order to protect blood vessels by enhancing anti-oxidative activity.
机译:细胞外超氧化物歧化酶(基因名称SOD3)是一种分泌的抗氧化酶,其在血管壁中的存在可能在保护血管系统免受氧化应激中起重要作用。氧化应激与糖尿病性视网膜病的发病机制有关。因此,已经提出增加细胞外超氧化物歧化酶可以抑制糖尿病性视网膜病的进展。基于肠促胰岛素的药物,例如胰高血糖素样肽-1受体激动剂,用于治疗2型糖尿病。由于胰高血糖素样肽-1受体不仅在胰腺组织中表达,而且在许多其他组织类型中表达,因此预期胰高血糖素样肽-1受体激动剂起胰外作用。我们在本文中证明了胰高血糖素样肽-1受体激动剂exendin-4通过表观遗传调控诱导人视网膜微血管内皮细胞中细胞外超氧化物歧化酶的表达。本研究的结果表明,exendin-4通过在SOD3近端启动子区域通过组蛋白H3乙酰化诱导细胞外超氧化物歧化酶的表达。此外,基于肠降血糖素的疗法可提高糖尿病患者血浆细胞外超氧化物歧化酶的浓度。因此,基于肠降血糖素的疗法可发挥直接的胰腺外作用,以通过增强抗氧化活性来保护血管。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号